

Rare diseases and specialised commissioning in England - genomics, research and access to medicine 9th January 2020

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt please contact the forum first.

Contents

About this Publication	3
Agenda	4
Session Chair's opening remarks Rt Hon the Baroness Neville-Jones, Vice-Chair, All-Party Parliamentary Group on Rare, Genetic and Undiagnosed Conditions (transcript)	6
The future for rare diseases policy in England and implementing the National Conomic Healthcare Stratogy	
The future for rare diseases policy in England and implementing the National Genomic Healthcare Strategy Professor Dame Sue Hill, Chief Scientific Officer, NHS England (transcript)	7
Questions and comments from the floor (transcript)	11
Assessing the implementation of the UK Strategy for Rare Diseases and key issues for patients	
Dr Jayne Spink, Chief Executive, Genetic Alliance UK (transcript)	14
Next steps for delivering specialised services for rare diseases: workforce and training, patient engagement and	
co-ordinating care	
Dr Robin Lachmann, Consultant, Metabolic Medicine, University College London Hospitals	
NHS Foundation Trust (transcript)	17
Dr Anneke Seller, Scientific Director, Genomics Education Programme, Health Education England (transcript)	20
Sara Hunt, Chief Executive Officer, Alex, The Leukodystrophy Charity (transcript)	22
Angela McFarlane, Senior Market Development Director, UK and Ireland, IQVIA (transcript)	24
Questions and comments from the floor with Dr Jayne Spink , Chief Executive, Genetic Alliance UK (transcript)	26
Session Chair's closing remarks	
Rt Hon the Baroness Neville-Jones, Vice-Chair, All-Party Parliamentary Group on Rare,	
Genetic and Undiagnosed Conditions (transcript)	34
Session Chair's opening remarks	
Alex Sobel MP (transcript)	35
Priorities for rare disease research: investment, collaboration and innovation	
Dr Larissa Kerecuk , Rare Disease Lead and Consultant Paediatric Nephrologist, Birmingham Women's and Children's	
NHS Foundation Trust and Clinical Research Speciality Lead, Paediatrics, National Institute of Health Research Clinical	
Research Network West Midlands (transcript)	36
Utilising genomics and personalised medicine in diagnosis and treatment	
Dr Richard Scott, Clinical Lead, Rare Diseases, Genomics England (transcript)	39
Improving access to medicines for rare diseases	
Richard Eaton, Rare Conditions Franchise Lead, Roche (transcript)	42
Questions and comments from the floor (transcript)	44
The role of NICE in improving treatment for rare diseases: cost effectiveness, value and evaluation	
Helen Knight, Programme Director, Technology Appraisals and Highly Specialised Technologies, NICE (transcript)	50
Next steps for specialised commissioning: funding, integration and reducing variation	
Dr Ayesha Ali, Medical Advisor, Highly Specialised Services, NHS England (transcript)	53
Questions and comments from the floor (transcript)	57
Session Chair's and Westminster Health Forum closing remarks	
Alex Sobel MP (transcript)	60
Stephanie Thomson, Forum Lead, Westminster Health Forum (transcript)	61
List of Delegates Registered for Seminar	62
Contributor Biographies	68
About the Core Sponsors of the Westminster Health Forum	71

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

About this Publication

This publication reflects proceedings at the Westminster Health Forum policy conference: Rare diseases and specialised commissioning in England - genomics, research and access to medicine held on 9th January 2020. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum

UK Headquarters 4 Bracknell Beeches Old Bracknell Lane West Bracknell Berkshire RG12 7BW

T: 01344 864796 F: 01344 420121 publications@westminsterforumprojects.co.uk

Directors

Peter van Gelder Chris Whitehouse